Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C

Real-world data show IBSRELA cuts GI-related doctor visits for IBS-C patients.

What the company is saying

Ardelyx is highlighting new real-world evidence that IBSRELA (tenapanor) significantly reduces gastrointestinal-related healthcare resource utilization for adults with IBS-C. The company frames this as a meaningful improvement in patient outcomes, using specific data from a 470-patient analysis showing median GI-related visits fell from 4.5 to 3.0 annually after starting IBSRELA. Rajani Dinavahi, MD, Chief Medical Officer, emphasizes the broader impact of IBS-C on quality of life and the value of these findings for patient care. Ardelyx also draws attention to ongoing research, including a Phase 3 trial for tenapanor in chronic idiopathic constipation (CIC) and presentations on symptom burden and quality of life. The announcement is data-driven, with a confident but measured tone, and includes detailed safety information and adverse event rates. The company positions itself as committed to advancing evidence and expanding indications for its products.

What the data suggests

The analysis included 470 adults with IBS-C who began tenapanor at a national gastroenterology practice. Median GI-related healthcare visits dropped from 4.5 per year before treatment to 3.0 per year after, with a statistically significant P-value (<0.001). Subgroup analyses confirmed reductions in patients who had previously tried other IBS-C medications, regardless of BMI or comorbidity. Safety data show diarrhea in 16% of IBSRELA patients versus 4% for placebo, with severe diarrhea in 2.5%. Other adverse events included abdominal distension (3% vs <1%), flatulence (3% vs 1%), and dizziness (2% vs <1%). IBS-C affects an estimated 12 million people in the US. No financial performance data or sales figures are disclosed. The evidence supports the claim of reduced healthcare utilization, but commercial impact is not quantified.

Analysis

The announcement is primarily a factual disclosure of real-world clinical results for IBSRELA (tenapanor) in IBS-C patients, with statistically significant reductions in healthcare resource utilization supported by specific patient numbers and p-values. The majority of claims are realised and substantiated by numerical data, with only a minor portion referencing ongoing research or future studies (e.g., the Phase 3 CIC trial). There is no evidence of exaggerated or promotional language, and no large capital outlay or long-dated, uncertain returns are discussed. The tone is positive but proportionate to the evidence presented. The absence of financial metrics (revenue, profit, cash flow) means the signal cannot be strong_positive, but the clinical data are robust and transparent. The gap between narrative and evidence is minimal, with no hype detected.

Risk flags

• ●Safety remains a concern, with diarrhea reported in 16% of IBSRELA-treated patients and severe diarrhea in 2.5%, which could limit broader adoption or lead to discontinuation.
• ●The absence of financial data means the commercial impact of reduced healthcare utilization is unclear, leaving uncertainty about revenue growth or profitability from IBSRELA.
• ●Expansion into new indications such as CIC depends on future clinical trial outcomes, which are not yet available and could face regulatory or efficacy hurdles.

Bottom line

Ardelyx presents strong real-world evidence that IBSRELA reduces GI-related healthcare visits for IBS-C patients, supported by statistically significant data from 470 patients. The safety profile includes notable rates of diarrhea and other mild adverse events, which may affect uptake. No financial or sales data are provided, so the business impact remains unquantified. The company is pursuing further growth through a Phase 3 trial in CIC, but results and regulatory outcomes are pending. For investors, the key takeaway is that IBSRELA demonstrates clinical benefit in real-world use, but the translation to revenue or market share is not yet established. Monitoring future disclosures on sales performance and CIC trial results will be critical.

Announcement summary

(NASDAQ:ARDX) Ardelyx, Inc. announced results from a real-world analysis presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, showing that gastrointestinal-related healthcare resource utilization (GI-HCRU) dropped significantly after adults with irritable bowel syndrome with constipation (IBS-C) started IBSRELA (tenapanor). The analysis included 470 patients with IBS-C who initiated tenapanor at a national gastroenterology practice. Median GI-related HCRU decreased from 4.5 visits in the year before tenapanor initiation to 3.0 visits in the year after initiation (3.0 [IQR: 1, 6] vs. 4.5 [IQR: 2, 9]; P<0.001). Subgroup analyses showed significant reductions in GI-HCRU among patients who had previously tried at least one IBS-C medication, regardless of BMI or comorbidity burden. Ardelyx is also presenting data on the impact of IBS-C symptom burden on quality of life and the design and rationale of an ongoing Phase 3, 26-week randomized controlled study evaluating tenapanor in adults with chronic idiopathic constipation (CIC). Poster presentations at ACG 2026 include: 'Health Care Resource Utilization Decreases Among Patients with Constipation Predominant Irritable Bowel Syndrome Following Initiation of Tenapanor: A Real-World Analysis' (#P3082, Oct 12, 1:00–2:15 PM CT), 'A Phase 3, 26-Week Randomized Controlled Study to Assess Safety and Efficacy of Tenapanor for Treatment of Chronic Idiopathic Constipation in Adults: Design and Rationale' (#P5352, Oct 13, 1:00–2:15 PM CT), and 'High Symptom Severity Burden is Associated with Reduced Quality of Life in US Adults with Irritable Bowel Syndrome with Constipation' (#P5327, Oct 13, 1:00–2:15 PM CT). Ardelyx is sponsoring a Product Theater titled 'Expanding IBS-C Care with a First-in-Class Treatment' on October 12 at 2:30 PM CT, led by Dr. Aja McCutchen. IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), reducing sodium absorption in the small intestine and colon, accelerating intestinal transit time, and resulting in softer stool consistency. IBSRELA is indicated for the treatment of IBS-C in adults. IBSRELA is contraindicated in patients less than 6 years of age due to risk of serious dehydration, and its safety and effectiveness have not been established in patients less than 18 years of age. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%), and dizziness (2% vs <1%). IBS-C is estimated to affect 12 million people in the United States. Ardelyx has two commercial products approved in the United States, IBSRELA (tenapanor) and XPHOZAH (tenapanor), and its pipeline includes Phase 3 development of IBSRELA for CIC and RDX10531, a next-generation NHE3 inhibitor.

Disagree with this article?